Amplification of 11q13 in ovarian carcinoma

Lindsay A. Brown, Steve E. Kalloger, Melinda A. Miller, Le Ming Shih, Steven E. McKinney, Jennifer L. Santos, Ken Swenerton, Paul Spellman, Joe Gray, C. Blake Gilks, David G. Huntsman

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

Amplification at the 11q13 locus is commonly observed in breast, ovarian, head and neck, oral, and esophageal cancer. Studies of this region led to the identification of multiple amplicons containing several potential oncogenes including EMSY, PAK1, RSF1, and GAB2. Here, we investigate the amplification of the above four genes and their prognostic significance in histologically and clinically defined subsets of ovarian cancer. Amplification of all four genes was assessed by fluorescent in situ hybridization in tissue microarrays containing 538 clinically annotated ovarian carcinomas with 12 years of follow-up data. Overall, for the entire cohort, EMSY was amplified in 44 (16%) of 269 cases, PAK1 was amplified in 38 (15%) of 255 cases, RSF1 was amplified in 37 (12%) of 310 cases, and GAB2 was amplified in 41 (16%) of 255 cases. Amplification of EMSY, PAK1, RSF1, and GAB2 were all highly correlated with each other and with a serous histology. Univariate survival analysis showed that tumors with EMSY and RSF1 amplification were associated with a significantly worse outcome. A molecular inversion probe array was then used to study the 11q13 amplicon in 33 high grade serous carcinomas. The core of the amplicon mapped to a 6-Mb region encompassing EMSY, PAK1, RSF1, and GAB2. However, a second more telomeric amplicon was also observed for which no candidate genes have been identified. In summary, amplification of these four putative oncogenes from 11q13 in early ovarian cancer is associated with a serous histology and in the case of EMSYand RSF1 a poor outcome. These findings support the hypothesis that the 11q13 amplicon in ovarian cancer is likely driven by a cassette of genes rather than by a single oncogene. This article contains Supplementary Material available at http://www.interscience.wiley.com/jpages/1045-2257/ suppmat.

Original languageEnglish (US)
Pages (from-to)481-489
Number of pages9
JournalGenes Chromosomes and Cancer
Volume47
Issue number6
DOIs
StatePublished - Jun 2008
Externally publishedYes

Fingerprint

Oncogenes
Ovarian Neoplasms
Carcinoma
Genes
Histology
Molecular Probes
Mouth Neoplasms
Esophageal Neoplasms
Survival Analysis
Head and Neck Neoplasms
Fluorescence In Situ Hybridization
Breast
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Genetics
  • Medicine(all)

Cite this

Brown, L. A., Kalloger, S. E., Miller, M. A., Shih, L. M., McKinney, S. E., Santos, J. L., ... Huntsman, D. G. (2008). Amplification of 11q13 in ovarian carcinoma. Genes Chromosomes and Cancer, 47(6), 481-489. https://doi.org/10.1002/gcc.20549

Amplification of 11q13 in ovarian carcinoma. / Brown, Lindsay A.; Kalloger, Steve E.; Miller, Melinda A.; Shih, Le Ming; McKinney, Steven E.; Santos, Jennifer L.; Swenerton, Ken; Spellman, Paul; Gray, Joe; Gilks, C. Blake; Huntsman, David G.

In: Genes Chromosomes and Cancer, Vol. 47, No. 6, 06.2008, p. 481-489.

Research output: Contribution to journalArticle

Brown, LA, Kalloger, SE, Miller, MA, Shih, LM, McKinney, SE, Santos, JL, Swenerton, K, Spellman, P, Gray, J, Gilks, CB & Huntsman, DG 2008, 'Amplification of 11q13 in ovarian carcinoma', Genes Chromosomes and Cancer, vol. 47, no. 6, pp. 481-489. https://doi.org/10.1002/gcc.20549
Brown LA, Kalloger SE, Miller MA, Shih LM, McKinney SE, Santos JL et al. Amplification of 11q13 in ovarian carcinoma. Genes Chromosomes and Cancer. 2008 Jun;47(6):481-489. https://doi.org/10.1002/gcc.20549
Brown, Lindsay A. ; Kalloger, Steve E. ; Miller, Melinda A. ; Shih, Le Ming ; McKinney, Steven E. ; Santos, Jennifer L. ; Swenerton, Ken ; Spellman, Paul ; Gray, Joe ; Gilks, C. Blake ; Huntsman, David G. / Amplification of 11q13 in ovarian carcinoma. In: Genes Chromosomes and Cancer. 2008 ; Vol. 47, No. 6. pp. 481-489.
@article{851c57a18906478287fabb66e0359cd0,
title = "Amplification of 11q13 in ovarian carcinoma",
abstract = "Amplification at the 11q13 locus is commonly observed in breast, ovarian, head and neck, oral, and esophageal cancer. Studies of this region led to the identification of multiple amplicons containing several potential oncogenes including EMSY, PAK1, RSF1, and GAB2. Here, we investigate the amplification of the above four genes and their prognostic significance in histologically and clinically defined subsets of ovarian cancer. Amplification of all four genes was assessed by fluorescent in situ hybridization in tissue microarrays containing 538 clinically annotated ovarian carcinomas with 12 years of follow-up data. Overall, for the entire cohort, EMSY was amplified in 44 (16{\%}) of 269 cases, PAK1 was amplified in 38 (15{\%}) of 255 cases, RSF1 was amplified in 37 (12{\%}) of 310 cases, and GAB2 was amplified in 41 (16{\%}) of 255 cases. Amplification of EMSY, PAK1, RSF1, and GAB2 were all highly correlated with each other and with a serous histology. Univariate survival analysis showed that tumors with EMSY and RSF1 amplification were associated with a significantly worse outcome. A molecular inversion probe array was then used to study the 11q13 amplicon in 33 high grade serous carcinomas. The core of the amplicon mapped to a 6-Mb region encompassing EMSY, PAK1, RSF1, and GAB2. However, a second more telomeric amplicon was also observed for which no candidate genes have been identified. In summary, amplification of these four putative oncogenes from 11q13 in early ovarian cancer is associated with a serous histology and in the case of EMSYand RSF1 a poor outcome. These findings support the hypothesis that the 11q13 amplicon in ovarian cancer is likely driven by a cassette of genes rather than by a single oncogene. This article contains Supplementary Material available at http://www.interscience.wiley.com/jpages/1045-2257/ suppmat.",
author = "Brown, {Lindsay A.} and Kalloger, {Steve E.} and Miller, {Melinda A.} and Shih, {Le Ming} and McKinney, {Steven E.} and Santos, {Jennifer L.} and Ken Swenerton and Paul Spellman and Joe Gray and Gilks, {C. Blake} and Huntsman, {David G.}",
year = "2008",
month = "6",
doi = "10.1002/gcc.20549",
language = "English (US)",
volume = "47",
pages = "481--489",
journal = "Genes Chromosomes and Cancer",
issn = "1045-2257",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Amplification of 11q13 in ovarian carcinoma

AU - Brown, Lindsay A.

AU - Kalloger, Steve E.

AU - Miller, Melinda A.

AU - Shih, Le Ming

AU - McKinney, Steven E.

AU - Santos, Jennifer L.

AU - Swenerton, Ken

AU - Spellman, Paul

AU - Gray, Joe

AU - Gilks, C. Blake

AU - Huntsman, David G.

PY - 2008/6

Y1 - 2008/6

N2 - Amplification at the 11q13 locus is commonly observed in breast, ovarian, head and neck, oral, and esophageal cancer. Studies of this region led to the identification of multiple amplicons containing several potential oncogenes including EMSY, PAK1, RSF1, and GAB2. Here, we investigate the amplification of the above four genes and their prognostic significance in histologically and clinically defined subsets of ovarian cancer. Amplification of all four genes was assessed by fluorescent in situ hybridization in tissue microarrays containing 538 clinically annotated ovarian carcinomas with 12 years of follow-up data. Overall, for the entire cohort, EMSY was amplified in 44 (16%) of 269 cases, PAK1 was amplified in 38 (15%) of 255 cases, RSF1 was amplified in 37 (12%) of 310 cases, and GAB2 was amplified in 41 (16%) of 255 cases. Amplification of EMSY, PAK1, RSF1, and GAB2 were all highly correlated with each other and with a serous histology. Univariate survival analysis showed that tumors with EMSY and RSF1 amplification were associated with a significantly worse outcome. A molecular inversion probe array was then used to study the 11q13 amplicon in 33 high grade serous carcinomas. The core of the amplicon mapped to a 6-Mb region encompassing EMSY, PAK1, RSF1, and GAB2. However, a second more telomeric amplicon was also observed for which no candidate genes have been identified. In summary, amplification of these four putative oncogenes from 11q13 in early ovarian cancer is associated with a serous histology and in the case of EMSYand RSF1 a poor outcome. These findings support the hypothesis that the 11q13 amplicon in ovarian cancer is likely driven by a cassette of genes rather than by a single oncogene. This article contains Supplementary Material available at http://www.interscience.wiley.com/jpages/1045-2257/ suppmat.

AB - Amplification at the 11q13 locus is commonly observed in breast, ovarian, head and neck, oral, and esophageal cancer. Studies of this region led to the identification of multiple amplicons containing several potential oncogenes including EMSY, PAK1, RSF1, and GAB2. Here, we investigate the amplification of the above four genes and their prognostic significance in histologically and clinically defined subsets of ovarian cancer. Amplification of all four genes was assessed by fluorescent in situ hybridization in tissue microarrays containing 538 clinically annotated ovarian carcinomas with 12 years of follow-up data. Overall, for the entire cohort, EMSY was amplified in 44 (16%) of 269 cases, PAK1 was amplified in 38 (15%) of 255 cases, RSF1 was amplified in 37 (12%) of 310 cases, and GAB2 was amplified in 41 (16%) of 255 cases. Amplification of EMSY, PAK1, RSF1, and GAB2 were all highly correlated with each other and with a serous histology. Univariate survival analysis showed that tumors with EMSY and RSF1 amplification were associated with a significantly worse outcome. A molecular inversion probe array was then used to study the 11q13 amplicon in 33 high grade serous carcinomas. The core of the amplicon mapped to a 6-Mb region encompassing EMSY, PAK1, RSF1, and GAB2. However, a second more telomeric amplicon was also observed for which no candidate genes have been identified. In summary, amplification of these four putative oncogenes from 11q13 in early ovarian cancer is associated with a serous histology and in the case of EMSYand RSF1 a poor outcome. These findings support the hypothesis that the 11q13 amplicon in ovarian cancer is likely driven by a cassette of genes rather than by a single oncogene. This article contains Supplementary Material available at http://www.interscience.wiley.com/jpages/1045-2257/ suppmat.

UR - http://www.scopus.com/inward/record.url?scp=43049170262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43049170262&partnerID=8YFLogxK

U2 - 10.1002/gcc.20549

DO - 10.1002/gcc.20549

M3 - Article

C2 - 18314909

AN - SCOPUS:43049170262

VL - 47

SP - 481

EP - 489

JO - Genes Chromosomes and Cancer

JF - Genes Chromosomes and Cancer

SN - 1045-2257

IS - 6

ER -